Cargando…

SUCCOR Risk: Design and Validation of a Recurrence Prediction Index for Early-Stage Cervical Cancer

OBJECTIVE: Based on the SUCCOR study database, our primary objective was to identify the independent clinical pathological variables associated with the risk of relapse in patients with stage IB1 cervical cancer who underwent a radical hysterectomy. Our secondary goal was to design and validate a ri...

Descripción completa

Detalles Bibliográficos
Autores principales: Manzour, Nabil, Chiva, Luis, Chacón, Enrique, Martin-Calvo, Nerea, Boria, Felix, Minguez, José A., Alcazar, Juan L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9246807/
https://www.ncbi.nlm.nih.gov/pubmed/35430668
http://dx.doi.org/10.1245/s10434-022-11671-5
_version_ 1784739035775762432
author Manzour, Nabil
Chiva, Luis
Chacón, Enrique
Martin-Calvo, Nerea
Boria, Felix
Minguez, José A.
Alcazar, Juan L.
author_facet Manzour, Nabil
Chiva, Luis
Chacón, Enrique
Martin-Calvo, Nerea
Boria, Felix
Minguez, José A.
Alcazar, Juan L.
author_sort Manzour, Nabil
collection PubMed
description OBJECTIVE: Based on the SUCCOR study database, our primary objective was to identify the independent clinical pathological variables associated with the risk of relapse in patients with stage IB1 cervical cancer who underwent a radical hysterectomy. Our secondary goal was to design and validate a risk predictive index (RPI) for classifying patients depending on the risk of recurrence. METHODS: Overall, 1116 women were included from January 2013 to December 2014. We randomly divided our sample into two cohorts: discovery and validation cohorts. The test group was used to identify the independent variables associated with relapse, and with these variables, we designed our RPI. The index was applied to calculate a relapse risk score for each participant in the validation group. RESULTS: A previous cone biopsy was the most significant independent variable that lowered the rate of relapse (odds ratio [OR] 0.31, 95% confidence interval [CI] 0.17–0.60). Additionally, patients with a tumor diameter >2 cm on preoperative imaging assessment (OR 2.15, 95% CI 1.33–3.5) and operated by the minimally invasive approach (OR 1.61, 95% CI 1.00–2.57) were more likely to have a recurrence. Based on these findings, patients in the validation cohort were classified according to the RPI of low, medium, or high risk of relapse, with rates of 3.4%, 9.8%, and 21.3% observed in each group, respectively. With a median follow-up of 58 months, the 5-year disease-free survival rates were 97.2% for the low-risk group, 88.0% for the medium-risk group, and 80.5% for the high-risk group (p < 0.001). CONCLUSION: Previous conization to radical hysterectomy was the most powerful protective variable of relapse. Our risk predictor index was validated to identify patients at risk of recurrence. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1245/s10434-022-11671-5.
format Online
Article
Text
id pubmed-9246807
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-92468072022-07-02 SUCCOR Risk: Design and Validation of a Recurrence Prediction Index for Early-Stage Cervical Cancer Manzour, Nabil Chiva, Luis Chacón, Enrique Martin-Calvo, Nerea Boria, Felix Minguez, José A. Alcazar, Juan L. Ann Surg Oncol Gynecologic Oncology OBJECTIVE: Based on the SUCCOR study database, our primary objective was to identify the independent clinical pathological variables associated with the risk of relapse in patients with stage IB1 cervical cancer who underwent a radical hysterectomy. Our secondary goal was to design and validate a risk predictive index (RPI) for classifying patients depending on the risk of recurrence. METHODS: Overall, 1116 women were included from January 2013 to December 2014. We randomly divided our sample into two cohorts: discovery and validation cohorts. The test group was used to identify the independent variables associated with relapse, and with these variables, we designed our RPI. The index was applied to calculate a relapse risk score for each participant in the validation group. RESULTS: A previous cone biopsy was the most significant independent variable that lowered the rate of relapse (odds ratio [OR] 0.31, 95% confidence interval [CI] 0.17–0.60). Additionally, patients with a tumor diameter >2 cm on preoperative imaging assessment (OR 2.15, 95% CI 1.33–3.5) and operated by the minimally invasive approach (OR 1.61, 95% CI 1.00–2.57) were more likely to have a recurrence. Based on these findings, patients in the validation cohort were classified according to the RPI of low, medium, or high risk of relapse, with rates of 3.4%, 9.8%, and 21.3% observed in each group, respectively. With a median follow-up of 58 months, the 5-year disease-free survival rates were 97.2% for the low-risk group, 88.0% for the medium-risk group, and 80.5% for the high-risk group (p < 0.001). CONCLUSION: Previous conization to radical hysterectomy was the most powerful protective variable of relapse. Our risk predictor index was validated to identify patients at risk of recurrence. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1245/s10434-022-11671-5. Springer International Publishing 2022-04-16 2022 /pmc/articles/PMC9246807/ /pubmed/35430668 http://dx.doi.org/10.1245/s10434-022-11671-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Gynecologic Oncology
Manzour, Nabil
Chiva, Luis
Chacón, Enrique
Martin-Calvo, Nerea
Boria, Felix
Minguez, José A.
Alcazar, Juan L.
SUCCOR Risk: Design and Validation of a Recurrence Prediction Index for Early-Stage Cervical Cancer
title SUCCOR Risk: Design and Validation of a Recurrence Prediction Index for Early-Stage Cervical Cancer
title_full SUCCOR Risk: Design and Validation of a Recurrence Prediction Index for Early-Stage Cervical Cancer
title_fullStr SUCCOR Risk: Design and Validation of a Recurrence Prediction Index for Early-Stage Cervical Cancer
title_full_unstemmed SUCCOR Risk: Design and Validation of a Recurrence Prediction Index for Early-Stage Cervical Cancer
title_short SUCCOR Risk: Design and Validation of a Recurrence Prediction Index for Early-Stage Cervical Cancer
title_sort succor risk: design and validation of a recurrence prediction index for early-stage cervical cancer
topic Gynecologic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9246807/
https://www.ncbi.nlm.nih.gov/pubmed/35430668
http://dx.doi.org/10.1245/s10434-022-11671-5
work_keys_str_mv AT manzournabil succorriskdesignandvalidationofarecurrencepredictionindexforearlystagecervicalcancer
AT chivaluis succorriskdesignandvalidationofarecurrencepredictionindexforearlystagecervicalcancer
AT chaconenrique succorriskdesignandvalidationofarecurrencepredictionindexforearlystagecervicalcancer
AT martincalvonerea succorriskdesignandvalidationofarecurrencepredictionindexforearlystagecervicalcancer
AT boriafelix succorriskdesignandvalidationofarecurrencepredictionindexforearlystagecervicalcancer
AT minguezjosea succorriskdesignandvalidationofarecurrencepredictionindexforearlystagecervicalcancer
AT alcazarjuanl succorriskdesignandvalidationofarecurrencepredictionindexforearlystagecervicalcancer
AT succorriskdesignandvalidationofarecurrencepredictionindexforearlystagecervicalcancer